Deaths and disability from natalizumab are no longer tolerable: Yes.
Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. pierre.duquette.1@umontreal.ca
Pierre
P
Duquette
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D004185:Disability Evaluation; D006801:Humans; D007049:Iatrogenic Disease; D007155:Immunologic Factors / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis / Q000401:mortality; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab; D061214:Patient Safety; D018579:Patient Selection; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab